Hutchison China Meditech Ltd (HCM)

 

Latest News

Block listing Interim Review

RNS Number: 4748A Hutchison China Meditech Limited 29 December 2017 Blocklisting Six Monthly Return London: Friday, December 29, 201 7: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutchison Chi...

Total Voting Rights

RNS Number: 4732A Hutchison China Meditech Limited 29 December 2017 Total Voting Rights London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordinary shares of US...

Chi-Med initiates fruquintinib clinical trials in US

Hutchison China MediTech has initiated the US phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly sele...

Chi-Med Initiates Fruquintinib US Clinical Trials

RNS Number: 4687Z Hutchison China Meditech Limited 15 December 2017 Press Release Chi-Med Initiates Fruquintinib U.S. Clinical Trials London: Friday , December 15 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent...

All News

DateHeadlineSource
29-12-17Block listing Interim ReviewRNS
29-12-17Total Voting RightsRNS
15-12-17Chi-Med initiates fruquintinib clinical trials in USStockMarketWire
15-12-17Chi-Med Initiates Fruquintinib US Clinical TrialsRNS
01-11-17Notification of Major HoldingsRNS
01-11-17NOTIFICATION OF MAJOR HOLDINGSRNS
31-10-17Chi-Med starts clinical trial of Inhibitor for gastric cancer patients StockMarketWire
31-10-17FRUTIGA, a Phase III trial of FruquintinibRNS
30-10-17Closing of U.S. Public Offering of ADSsRNS
27-10-17Chi-Med Announces Over-allotment OptionRNS
26-10-17Chi-Med prices US public offering StockMarketWire
26-10-17Chi-Med Announces Pricing Raising US$262 millionRNS
25-10-17Chi-Med plans $262m offering on Nasdaq StockMarketWire
25-10-17Chi-Med Announces Proposed Offering of ADSsRNS
19-10-17Notification of Major Interest in SharesRNS
17-10-17Chi-Med and AZ present encouraging data on lung cancer drug StockMarketWire
17-10-17Savolitinib Shows Encouraging Clinical ActivityRNS
16-10-17Chi-Med reports 'promising data' on lung cancer drugStockMarketWire
16-10-17Chi-Med Reports Preliminary Phase II dataRNS
12-10-17Appointment of DirectorRNS
29-09-17Best AIM companies of 2017 Interactive Investor
29-09-17Savolitinib and Fruquintinib presentations at WCLCRNS
29-09-17Total Voting RightsRNS
29-09-17Oral Presentations at CSCO Annual MeetingRNS
31-08-17Director's Share DealingRNS
29-08-17Chi-Med starts clinical trial of Inhibitor in lymphoma patients StockMarketWire
29-08-17Start of HMPL 689 Phase I Trial in ChinaRNS
22-08-17Director's Share DealingRNS
18-08-17Directors' Share DealingRNS
15-08-17Directors' Share DealingRNS
10-08-17Director's Share DealingRNS
07-08-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
07-08-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
07-08-17Directors' Share DealingRNS
31-07-17Chi-Med revenues up 21%StockMarketWire
31-07-17Chi-Med Reports 2017 Interim ResultsRNS
30-06-17Total Voting RightsRNS
29-06-17Chi-Med and AZ start global trial of renal cancer drug StockMarketWire
29-06-17Start of Savolitinib Global PRCC Phase III TrialRNS
29-06-17Chi-Med to Announce 2017 HY Financial ResultsRNS

RSS feeds

  • Editorial news feed for LSE:HCM Editorial
  • Regulatory news feed for LSE:HCM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account